|
Ding WY, Rivera-Caravaca JM, Marin F, Li G, Roldan V, Lip GYH. Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence. Br J Clin Pharmacol. 2022 Jan;88(1):282-289. doi: 10.1111/bcp.14961. Epub 2021 Jul 13. PubMed PMID: 34192808.
AÑO: 2022; IF: 3.4
|
34192808
|
de Los Reyes-Garcia AM, Rivera-Caravaca JM, Zapata-Martinez L, Aguila S, Veliz-Martinez A, Garcia-Barbera N, Gil-Perez P, Guijarro-Carrillo PJ, Orenes-Pinero E, Lopez-Garcia C, Lozano ML, Marin F, Martinez C, Gonzalez-Conejero R. MiR-146a Contributes to Thromboinflammation and Recurrence in Young Patients with Acute Myocardial Infarction. J Pers Med. 2022 Jul 20;12(7):1185. doi: 10.3390/jpm12071185. PubMed PMID: 35887682; PubMed Central PMCID: PMC9318357.
AÑO: 2022; IF: 3.508
|
|
Esteve-Pastor MA, Rivera-Caravaca JM, Ruiz-Ortiz M, Muniz J, Roldan-Rabadan I, Otero D, Lopez-Galvez R, Cequier A, Bertomeu-Martinez V, Badimon L, Anguita M, Lip GYH, Marin F; FANTASIIA investigators. A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry. Expert Opin Pharmacother. 2022 Aug;23(12):1457-1465. doi: 10.1080/14656566.2022.2109961. Epub 2022 Aug 12. PubMed PMID: 35924672.
AÑO: 2022; IF: 3.2
|
|
Santoro F, Nunez-Gil IJ, Vitale E, Viana-Llamas MC, Romero R, Maroun Eid C, Feltes Guzman G, Becerra-Munoz VM, Fernandez Rozas I, Uribarri A, Alfonso-Rodriguez E, Garcia Aguado M, Huang J, Castro Mejia AF, Garcia Prieto JF, Elola J, Ugo F, Cerrato E, Signes-Costa J, Raposeiras Roubin S, Jativa Mendez JL, Espejo Paeres C, Lopez Masjuan A, Marin F, Guerra F, El-Battrawy I, Cortese B, Ramakrishna H, Perez-Villacastin J, Fernandez-Ortiz A, Brunetti ND. Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry. J Am Heart Assoc. 2022 Jul 5;11(13):e024530. doi: 10.1161/JAHA.121.024530. Epub 2022 Jun 22. PubMed PMID: 35730631; PubMed Central PMCID: PMC9333361.
AÑO: 2022; IF: 6.106
|
|
Lopez-Galvez R, Rivera-Caravaca JM, Anguita Sanchez M, Sanmartin Fernandez M, Rafols C, Perez-Cabeza AI, Baron Esquivias G, Lekuona Goya I, Vazquez Rodriguez JM, Cosin Sales J, Arribas Ynsaurriaga F, Barrios V, Freixa-Pamias R, Marin F. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788. Epub 2022 Apr 14. PubMed PMID: 35395094.
AÑO: 2022; IF: 5.5
|